Publications by authors named "Helene Pasquer"

Claim this Profile
O
Outcome of patients with accelerated and blast-phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination-A FIM study.
Corentin Orvain, Suzanne Tavitian, Clémence Mediavilla, Françoise Boyer, Alberto Santagostino, Hélène Pasquer

Hemasphere· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AML patient blasts exhibit polarization defects upon interaction with bone marrow stromal cells.
Khansa Saadallah, Benoît Vianay, Louise Bonnemay, Hélène Pasquer, Lois Kelly

EMBO Rep· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms.
Nabih Maslah, Nina Kaci, Blandine Roux, Gabriela Alexe, Raphael Marie, Hélène Pasquer

Nat Commun· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current myeloproliferative neoplasm scoring systems for clinical practice.
Hélène Pasquer, Jean-Jacques Kiladjian, Lina Benajiba

Blood· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
INA03: A Potent Transferrin-Competitive Antibody-Drug Conjugate against CD71 for Safer Acute Leukemia Treatment.
Manuela Bratti, Elisa Stubbs, Sergii Kolodych, Herve Souchet, Lois Kelly, Hélène Pasquer

Mol Cancer Ther· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting a lineage-specific PI3Kɣ-Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader molecule.
Lois M Kelly, Justine C Rutter, Kevin H Lin, Frank Ling, Matthieu Duchmann, Hélène Pasquer

Nat Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative clinical and molecular landscape of primary and secondary myelofibrosis: Superior performance of MIPSS70+ v2.0 over MYSEC-PM.
Matteo Guerra, Hélène Pasquer, Rafael Daltro de Oliveira, Juliette Soret-Dulphy, Nabih Maslah

Am J Hematol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification.
Hélène Pasquer, Rafael Daltro de Oliveira, Loic Vasseur, Juliette Soret-Dulphy, Nabih Maslah

Leukemia· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can Some Anticancer Treatments Preserve the Ovarian Reserve?
Nicolas Vallet, Nicolas Boissel, Elisabeth Elefant, Florian Chevillon, Hélène Pasquer

Oncologist· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax induces profound and sustained responses in patients with relapsed/refractory light-chain amyloidosis.
Hélène Pasquer, Karim Belhadj, Jehan Dupuis, Sylvia Oghina, Antoine Galat

Br J Haematol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Descriptive and Functional Genomics in Acute Myeloid Leukemia (AML): Paving the Road for a Cure.
Hélène Pasquer, Maëlys Tostain, Nina Kaci, Blandine Roux, Lina Benajiba

Cancers (Basel)· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis